Abstracts tagged "B-Cell Targets"

Abstract Number: 2488 • ACR Convergence 2025
Efficacy and Safety of Rituximab for Skin Involvement in Systemic Sclerosis: A Single-Center Study
Kanako Chujo¹, Taichi Miyagi¹, Hiromi Shimada², Shusaku Nakashima², Yusuke Ushio¹, Koichi Sugihara², Mao Mizusaki², Naoto Manabe¹, Mayuko Wada², Risa Wakiya³ and Hiroaki Dobashi², ¹Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ²Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Kagawa, Japan, ³Division of Rheumatology, Departent of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Rituximab (RTX) was approved in Japan as a new treatment strategy for systemic sclerosis (SSc). Intravenous rituximab (375mg/m2) is administered once a week for…
Abstract Number: 1766 • ACR Convergence 2025
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
caterina ricordi¹, Maxime Beydon², Johanne Liberatore³, Pascal Cohen⁴, bertrand Dunogue⁵, Camille Mettler⁶, Benjamin Torreau⁷, Luc Mouthon⁵, Xavier Puéchal⁸ and Benjamin Terrier⁹, ¹Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, ²Sorbonne University, INSERM, Institut Pierre Louis of Epidemiology and Public Health, Equipe PEPITES, Pitié Salpêtrière Hospital, Service of Public Health, Centre of Pharmacoepidemiology (Cephepi), Paris, France, ³Department of Internal Medicine, Centre Hospitalier d’Angouleme, Angouleme, France, ⁴Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, Paris, France, ⁵Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP, Paris, France, ⁶Department of Internal Medicine, Hôpital Bichat - Claude-Bernard, Paris, France, ⁷Internal Medicine and Immunology, CHU Tours, Tours, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( ⁷⁵⁰¹⁴ ), Ile-de-France, France, ⁹Cochin Hospital, Paris, France
Background/Purpose: Rituximab (RTX) is the standard of care for both induction and maintenance in ANCA-associated vasculitides (AAVs). While CD19 B-cell monitoring is used to evaluate…
Abstract Number: 1163 • ACR Convergence 2025
Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
John Stone¹, Emma Culver², Arezou Khosroshahi³, Wen Zhang⁴, Emanuel Della Torre⁵, Kazuichi Okazaki⁶, Yoshiya Tanaka⁷, Matthias Lohr⁸, nicolas schleinitz⁹, Fernando Martinez-Valle¹⁰, Manu Nayar¹¹, Vinciane Rebours¹², Cory Perugino¹³, Kristen Clarkson¹⁴, Theresa Alexander¹⁴, Xinxin Dong¹⁴, Qian Huang¹⁴, Sue Cheng¹⁴ and Daniel Cimbora¹⁴, ¹Massachusetts General Hospital , Harvard Medical School, Concord, MA, ²John Radcliffe Hospital; University of Oxford, Oxford, United Kingdom, ³Emory University, Atlanta, GA, ⁴Peking Union Medical College Hospital, Dong Cheng Qu, China (People's Republic), ⁵IRCCS San Raffaele Scientific Institute, Milan, Italy, ⁶Kansai Medical University Kori Hospital, Osaka, Japan, ⁷University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁸Karolinska Institutet, Stockholm, Sweden, ⁹Aix Marseille university, AP-HM, Marseille, France, ¹⁰Vall d’Hebron Hospital, Barcelona, Spain, ¹¹Freeman Hospital, Newcastle upon Tyne, United Kingdom, ¹²Beaujon Hospital, AP-HP, Université Paris-Cité, Clichy, France, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Amgen, Thousand Oaks, CA
Background/Purpose: IgG4-RD is a rare, chronic, fibroinflammatory disorder characterized by recurrent flares that can affect any organ and lead to permanent tissue damage. Inebilizumab (INEB)…
Abstract Number: 0897 • ACR Convergence 2025
APECED Disease Reorganizes The B Cell Compartment Toward Alternatively Activated Subsets
william Galbavy, Hyunjin Kim, Brian Klotz, Marine Malbec, Carley Tasker, Eva Conde, Andrea Vecchione, Seblewongel Asrat, Benjamin Daniel, Weikeat Lim, Andre Limnander and Jamie Orengo, Regeneron, Tarrytown, NY
Background/Purpose: Autoimmune PolyEndocrinopathy Candidiasis Ectodermal Dystrophy (APECED) is a rare syndrome of multi-organ autoimmunity driven by the presence of self-reactive T cells and autoantibodies caused…
Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Philipp Richle, Stephanie Jungmichel, Alessio Vantellini, André Fonseca, Anna Howald, Fabian Scheifele, Loredana iuliano, Ariadna Vilarrasa, Romina Doerig, Hannes Merten, Philip Knobel, Daniel Lenherr-Frey, Christian Leisner and Leonardo Borras, CDR-Life, Horgen, Zurich, Switzerland
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…
Abstract Number: 2454 • ACR Convergence 2025
Longitudinal Analysis of B cell Remodeling in Systemic Lupus Erythematosus Following iPSC-Derived CAR T-cell Therapy
Jonatan Tuncel¹, Trever Greene², Nicholas Brookhouser², Sandeep Kothapally Hanok¹, Seth Peng¹, Alison O’Conor¹, Parastoo Fazeli³, Jennifer Medlin⁴, Cara Bickers², Kelsea Hubka¹, Allison Aguilar¹, Wei Zhao¹, Kyla Omilusik¹, John Goulding¹, Tom Lee², Jode Goodridge², Marie Hu⁵, Veronika Bachanova⁵, Jeffrey Miller⁶, Matthew Lunning⁷, Rebecca Elstrom², Debra Zack¹, Vaneet Sandhu², Bahram Valamehr⁸ and Lilly Wong⁸, ¹Fate Therapeutics, San Diego, ²Fate Therapeutics, Inc., San Diego, ³UMN, ST PAUL, MN, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Minnesota, Minneapolis, ⁶University of Minnesota, Minneaspolis, MN, ⁷University of Nebraska Medical Center, Omaha, ⁸Fate Therapeutics, Inc., San Diego, CA
Background/Purpose: Autologous chimeric antigen receptor (CAR) T-cell therapy is an exciting new potential therapy for autoimmune diseases but limited in scope of application by logistical…
Abstract Number: 1761 • ACR Convergence 2025
The Application of SLE Patient-derived PBMC-induced Mouse Model in Preclinical Pharmacological Studies
Juan Liang¹, Yinlian Zhang², Feng Li², Yingfeng Huang³, Ruixia Zhang³ and Ruixue Dai³, ¹Gempharmatech, Nanjing, Jiangsu, China, ²GemPharmatech, Nanjing, China (People's Republic), ³CytoCares, Shanghai, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder characterized by the production of autoantibodies targeting nuclear antigens, immune complex deposition, and chronic inflammation…
Abstract Number: 1109 • ACR Convergence 2025
Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
Laurianne Simard¹, Nathalie Amiable², Ines Colmegna³, Anne-Sophie Julien⁴, Sonia Léger-Thériault⁵, Alexandra Godbout⁴, Lison Fournier⁶, Giuliana Alfonso⁵, Josiane Bourre-Tessier⁷, Marie Hudson⁸, Nicolas Richard⁹, Jean-Paul Makhzoum¹⁰, Arielle Mendel¹¹, Sasha Bernatsky¹², Marc Dionne⁶, Michael Libman⁵, Gaston De Serres⁶ and Paul Fortin¹³, ¹Universite Laval, Quebec, QC, Canada, ²Centre de recherche du CHU de Québec – Université Laval, Quebec City, QC, Canada, ³The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ⁴Centre de recherche du CHU de Québec – Université Laval, Quebec, QC, Canada, ⁵MUHC, Montreal, Canada, ⁶Centre de recherche du CHU de Québec – Université Laval, Quebec, Canada, ⁷Centre hospitalier de l'Universite de Montreal, Montreal, QC, Canada, ⁸McGill University, Montréal, QC, Canada, ⁹Hopital Maisonneuve Rosemont, Montreal, QC, Canada, ¹⁰Universite de Montreal, Montreal, Canada, ¹¹McGill University Health Centre, Montréal, QC, Canada, ¹²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹³Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARD) treated with B-cell-depleting therapies such as rituximab (RTX) have impaired humoral immune responses, increasing their susceptibility to…
Abstract Number: 0664 • ACR Convergence 2025
Pharmacodynamic Effects of Obinutuzumab on B cells and Serological Markers in Patients With Active Lupus Nephritis: Results From a Phase III Trial
Richard Furie¹, Ioannis Parodis², Rachel Jones³, Liz Lightstone⁴, Olivia Hwang⁵, Amelia Au-Yeung⁵, Imran Hassan⁶, Huiyan Mao⁶, William Pendergraft⁵, Jay Garg⁵, Harini Raghu⁵ and Brad Rovin⁷, ¹Division of Rheumatology, Northwell Health, Great Neck, NY, ²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ³Renal Medicine, Cambridge University Hospitals, Cambridge, England, United Kingdom, ⁴Department of Immunology and Inflammation, Faculty of Medicine, Imperial College London, London, England, United Kingdom, ⁵Genentech, Inc., South San Francisco, CA, ⁶Hoffmann-La Roche Ltd, Mississauga, ON, Canada, ⁷The Ohio State University, Columbus, OH
Background/Purpose: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus, marked by kidney inflammation and damage. Obinutuzumab, a glycoengineered, type II CD20 antibody…
Abstract Number: 0014 • ACR Convergence 2025
NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
Mira Tohmé, Meriam Vejiga, Wendy Yu, Emily Kang, Katharine Yu, Jessica Sood, Ivan Chan, Kyle Hansen, David Shook and Phung Gip, Nkarta, South San Francisco, CA
Background/Purpose: Autologous CAR T-cell therapies have remarkable clinical activity in autoimmune disease (AD) via B-cell targeting, with many patients achieving durable, drug-free remission. However, safety…
Abstract Number: 2476 • ACR Convergence 2025
Blinatumomab in rapid progressive systemic sclerosis
Christina Gebhardt¹, Franziska Szelinski², Hector Rincon-Arevalo², Giulia Magno³, Veit Buecklein³, Gerulf Haenel⁴, Gerhard Zugmaier⁵, Michael von Bergwelt³, Marion Subklewe³, Thomas Dörner⁶, Alla Skapenko⁷ and Hendrik Schulze-Koops⁷, ¹LMU Hospital, Division for Rheumatology and Clinical Immunology, München, Germany, ²Charite Universitétsmedizin Berlin, Germany, Berlin, Germany, ³LMU Klinikum, Med. Klinik und Poliklinik III, Munich, Germany, ⁴LMU Gene Center, Munich, Germany, ⁵Amgen, Munich, Germany, ⁶Charite Universitétsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany, ⁷LMU Hospital, Division for Rheumatology and Clinical Immunology, Munich, Bayern, Germany
Background/Purpose: Systemic sclerosis is a severe, potentially fatal disease, characterized by progressive fibrosis of skin and internal organs. Blinatumomab is a bispecific CD3/CD19-T-cell engager (BiTe)…
Abstract Number: 1697 • ACR Convergence 2025
Dynamic Effects of T cell Engager Therapy on B and T cells in Autoimmune Disease.
Laura Bucci¹, Tobias Rothe², Ann-Kathrin Goetz³, Kirill Anoshkin¹, Danae-Mona Nöthling¹, Melanie Hagen¹, Sebastian Böltz¹, Andreas Wirsching¹, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlagen, Germany, ³Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, ⁴Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany, ⁵University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Treatment of autoimmune disease with T cell engagers (TCEs) leads to profound peripheral B cell depletion, followed by their reconstitution. However, the dynamics of…
Abstract Number: 1093 • ACR Convergence 2025
Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Blake Baay¹, Lorien Nassi² and Zachary Most³, ¹Scottish Rite for Children, Dallas, TX, ²UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ³UT Southwestern, Dallas, TX
Background/Purpose: Rituximab is one of the many immunosuppressive medications used to treat SLE that can increase a patient’s risk for developing progressive multifocal leukoencephalopathy (PML),…
Abstract Number: 0656 • ACR Convergence 2025
Low-dose belimumab reduced disease flares in patients with systemic lupus erythematosus at low disease activity: a multicenter, randomized, double-blind, placebo-controlled trial
Fangfang Sun¹, Huijing Wang¹, Danting Zhang¹, Nan Shen¹, Sheng Chen¹, Tiing Li¹, Weiguo Wan², Shengming Dai³ and Shuang Ye⁴, ¹Renji Hospital, Shanghai, China (People's Republic), ²Huashan Hospital, Shanghai, China (People's Republic), ³Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China (People's Republic), ⁴Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)
Background/Purpose: B-lymphocyte stimulator was involved in the pathogenesis of SLE. The humanized monoclonal antibody belimumab with 10mg/kg was effective for active patients. The efficacy of…
Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Matthew Bernett¹, Gregory Moore², Katrina Bykova², Viralkumar Davra², Seung Chu², Michael Sheard², Ruschelle Love², Norman Barlow², Engie Salama², Jitendra Kanodia², Panida Lertkiatmongkol², Dipankar Chaudhuri², Kendra Avery², Hanh Nguyen², Rumana Rashid², Ke Liu², Jing Qi², Araz Eivazi², Thuy Truong², Sher Karki², James Ernst², Rena Bahjat² and John Desjarlais², ¹Xencor, Inc., Pasadena, CA, ²Xencor, Inc., Pasadena
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].